What is the fair value of Omeros Corporation (NASDAQ-OMER) stock?

The current fair value estimate for Omeros Corporation (NASDAQ-OMER) is $10.07. This implies an estimated downside of 43.7% versus the current market price.

Is Omeros Corporation (NASDAQ-OMER) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 43.7% versus the current market price.

What is the analyst price target for NASDAQ-OMER stock?

The available analyst price target for Omeros Corporation (NASDAQ-OMER) is $33. The analyst target implies estimated upside of 84.7%.

How is the financial health of Omeros Corporation?

The current financial health read for Omeros Corporation (NASDAQ-OMER) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Omeros Corporation's next earnings date?

The next earnings date currently listed for Omeros Corporation (NASDAQ-OMER) is November 11, 2026.

Does Omeros Corporation (NASDAQ-OMER) pay dividends?

The latest available data indicates no current dividend yield for Omeros Corporation (NASDAQ-OMER).

What is the P/E ratio for Omeros Corporation (NASDAQ-OMER)?

The current P/E ratio listed for Omeros Corporation (NASDAQ-OMER) is 11.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Omeros Corporation?

The current market capitalization listed for Omeros Corporation is 1.294 B.

What is the enterprise value of Omeros Corporation?

The current enterprise value listed for Omeros Corporation is 1.5 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Omeros Corporation?

The ticker symbol for Omeros Corporation is NASDAQ-OMER, and the stock is listed on NASDAQ.

Where is Omeros Corporation (NASDAQ-OMER) listed?

Omeros Corporation (NASDAQ-OMER) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Omeros Corporation?

The current debt-to-total-capital ratio listed for Omeros Corporation is 18.2%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Omeros Corporation?

The free float listed for Omeros Corporation is 95.7%. Free float helps investors understand how much of the share base is available for public trading.

Omeros Corporation (OMER) Fair Value & Stock Analysis

Omeros Corporation (OMER)

Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for immunologic diseases and orphan indications. Its lead candidate is narsoplimab (OMS721/MASP-2), which is being studied for thrombotic microangiopathy associated with hematopoietic stem-cell transplant, as well as in clinical trials for COVID-19 and acute respiratory distress syndrome. The company is also advancing OMS1029, zaltenibart, and OMS527 across multiple clinical programs, while further preclinical work includes MASP-2 and MASP-3 inhibitors, adoptive T-cell and immunostimulator combination therapies, and oncotoxins and immunomodulators for cancer-related research. Omeros was incorporated in 1994 and is headquartered in Seattle, Washington.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-OMER	$10.07	-43.7% Downside	Overvalued	$33	84.7% Upside	Bargain	Great	0.0%	November 11, 2026	11.5x	34.8x	1.294 B	1.5 B	18.2%	95.7%	-2.1	-59.0%